Goldman just cut its US stock forecast. It lays out 3 things that could spark a recovery.
Goldman's chief US equity strategist lowered his year-end price target for the S&P 500, but said there's a path to recovery for stocks.
Goldman's chief US equity strategist lowered his year-end price target for the S&P 500, but said there's a path to recovery for stocks.
Recession chatter is still making the rounds on Wall Street, but cooler inflation is quelling fears of a dire scenario for the Fed.
Investors are digesting better-than-expected inflation data and bracing for the next move in Trump's escalating trade war.
Wall Street thought the stock market would act as a check on the president. It's not panning out.
The CPI inflation report overshadowed the latest 'tit for tat' twist in the global trade war - U.S. President Donald Trump said he would slap further tariffs on European Union goods after the EU and other U.S. trading partners said they would retaliate for trade barriers already erected by the U.S. president. "Whatever they charge us, we're charging them," Trump said.
TSMC reportedly approached a handful of US AI chipmakers to potentially operate Intel's foundry in a joint venture.
Young adult apparel retailer American Eagle Outfitters (NYSE:AEO) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 4.4% year on year to $1.6 billion. On the other hand, next quarter’s revenue guidance of $1.09 billion was less impressive, coming in 6.7% below analysts’ estimates. Its non-GAAP profit of $0.54 per share was 6.3% above analysts’ consensus estimates.
Kohl’s shares slumped Wednesday, extending recent losses as Wall Street analysts suggested it could keep falling.
Healthcare technology company Phreesia (NYSE:PHR) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 15.4% year on year to $109.7 million. The company expects the full year’s revenue to be around $477 million, close to analysts’ estimates. Its GAAP loss of $0.11 per share was 35% above analysts’ consensus estimates.
Skincare company BeautyHealth (NASDAQ:SKIN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 13.7% year on year to $83.5 million. On the other hand, next quarter’s revenue guidance of $63.5 million was less impressive, coming in 16.6% below analysts’ estimates. Its GAAP loss of $0.08 per share was 30% above analysts’ consensus estimates.